Home › Bipolar Disorder › California › Anaheim
Bipolar Disorder clinical trials in Anaheim, CA
4 studies for Bipolar Disorder are looking for participants at sites in and around Anaheim (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
RecruitingPhase 3
- Advanced Research Center, Inc, Anaheim
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
RecruitingPhase 3
- Advanced Research Center, Inc, Anaheim
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
RecruitingPhase 2
- Advanced Research Center /ID# 272828, Anaheim
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RecruitingPhase 1
- BioXcel Clinical Research Site, Anaheim
About Bipolar Disorder
Bipolar disorder is a mood disorder that can cause intense mood swings. It's also called manic depression. Learn about the types, symptoms, treatment, and more.
More about Bipolar Disorder on MedlinePlus
Bipolar Disorder trials in other cities
- Houston, TX10 studies
- New York City, NY7 studies
- Boston, MA7 studies
- Little Rock, AR6 studies
- Atlanta, GA6 studies
- Miami, FL5 studies
- Hialeah, FL5 studies
- Austin, TX5 studies
- Cambridge, MA5 studies
- Orange, CA5 studies
- Everett, WA4 studies
- West Palm Beach, FL4 studies
Other studies in Anaheim
- Schizophrenia8 studies
- Non-Small Cell Lung Cancer8 studies
- Alzheimer's Disease7 studies
- Ulcerative Colitis7 studies
- Crohn's Disease6 studies
- Breast Cancer5 studies
- Lung Cancer4 studies
- Obesity4 studies
- Psychotic Disorders4 studies
- Migraine4 studies
- Irritable Bowel Syndrome3 studies
- Metastatic Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.